score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Preclinical			Copy Number	AURKB	Amplification				0.0	0.0		Putatively Actionable	Barasertib	Aurora-B kinase inhibition	Targeted therapy	MYC amplified small cell lung cancer	Helfrich BA, Kim J, Gao D, et al. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. Mol Cancer Ther. 2016;15(10):2314-2322.	https://doi.org/10.1158/1535-7163.MCT-16-0298													0				AURKB Amplification		Osteosarcoma-SJDOSTEOS008	SJDOSTEOS008-1	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	PRMT5 inhibition	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214													0				CDKN2A Deletion		Osteosarcoma-SJDOSTEOS008	SJDOSTEOS008-1	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 3	version 2	0.647						Investigate Actionability	Platinum	Platinum-based chemotherapy	Chemotherapy	Responders to platinum based chemotherapy exhibit COSMIC signature 3 (HR signature) mutations in pancreatic cancer.	Alexandrov LB, Nik-zainal S, Siu HC, Leung SY, Stratton MR. A mutational signature in gastric cancer suggests therapeutic strategies. Nat Commun. 2015;6:8683.	https://doi.org/10.1038/ncomms9683													0				COSMIC Signature (version 2) 3 (65%)		Osteosarcoma-SJDOSTEOS008		
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						Osteosarcoma-SJDOSTEOS008		
Investigate Actionability			Guideline	Copy Number	TP53	Amplification				0.0	0.0																Investigate Actionability	0.0	Deletion of 17p13 leads to LoH of TP53 and is considered a high-risk feature of multiple myeloma.	National Comprehensive Cancer Network. Multiple Myeloma NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/myeloma_blocks.pdf	0				TP53 Amplification		Osteosarcoma-SJDOSTEOS008	SJDOSTEOS008-1	
Biologically Relevant				Copy Number	CCND3	Amplification				0.0	0.0																					0				CCND3 Amplification		Osteosarcoma-SJDOSTEOS008	SJDOSTEOS008-1	
Biologically Relevant				Copy Number	MAP2K2	Deletion				0.0	0.0																					0				MAP2K2 Deletion		Osteosarcoma-SJDOSTEOS008	SJDOSTEOS008-1	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		Osteosarcoma-SJDOSTEOS008		
Biologically Relevant				Mutational Signature	COSMIC Signature 15	version 2	0.211																									0				COSMIC Signature (version 2) 15 (21%)		Osteosarcoma-SJDOSTEOS008		
